Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04186221 · ClinicalTrials.gov registry record · NA

OCS Liver PROTECT Continued Access Protocol

A NA study of Liver Transplant, sponsored by TransMedics.

Completed
Registry status
NA
Development phase
74
Enrollment target
17
Study locations

NCT04186221: Completed NA study of Liver Transplant, sponsored by TransMedics.

NCT04186221 is a NA study of Liver Transplant that has completed, run by TransMedics. The registered enrollment target is 74 participants, below the 5,454-participant average among 19 other Liver Transplant trials with a reported enrollment target (99% lower). The trial reports 17 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04186221, a NA study of Liver Transplant, has completed, sponsored by TransMedics.

COMPLETED
Registry status
NA
Development phase
74 participants
Enrollment target
17
Study locations

Study Summary

Continued Access Protocol to evaluate the effectiveness of the OCS Liver System to preserve and assess donor livers.

Primary Outcome

Participants with Early liver Allograft Dysfunction (EAD) or primary non-function, defined as presence of one or more of the following criteria: AST level \> 2000 IU/ml within the first 7 postoperative days; Bilirubin ≥ 10 mg/dl on postoperative day 7; INR ≥ 1.6 on postoperative day 7; or Primary non-functioning graft within the first 7 days (defined as irreversible graft dysfunction requiring emergency liver re-transplantation or death, in the absence of immunologic or surgical causes)

Conditions Studied

Interventions

  • DEVICE OCS Liver System

Study Locations (17)

California

  • Scripps - La Jolla
  • University of California San Diego - La Jolla
  • UCSF - San Francisco

Texas

  • University of Texas Southwest - Dallas
  • Houston Methodist Hospital - Houston
  • The University of Texas Health Science Center at San Antonio - San Antonio

New York

  • Mount Sinai Hospital - New York
  • Montefiore Einstein Center for Transplantation - The Bronx

Virginia

  • University of Virginia - Charlottesville
  • Virginia Commonwealth University Health System - Richmond

Florida

  • Tampa General - Tampa

Maryland

  • Johns Hopkins - Baltimore

Massachusetts

  • Massachusetts General Hospital - Boston

Michigan

  • Henry Ford Hospital - Detroit

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2020-02-03
Est. Completion 2023-02-02
Phase NA
TransMedics

23 total trials

What the finished NCT04186221 record still lists

NCT04186221 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 5,454-participant average among 19 other Liver Transplant trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Liver Transplant appearing as the primary indexed condition, and to 1 intervention - of which OCS Liver System is the first listed.

NCT04186221 lists 17 locations in 11 states (California, Texas, New York).

Frequently Asked Questions

What is clinical trial NCT04186221 about?

NCT04186221 is a clinical study titled "OCS Liver PROTECT Continued Access Protocol". Continued Access Protocol to evaluate the effectiveness of the OCS Liver System to preserve and assess donor livers.

What is the current status of trial NCT04186221?

This trial is currently completed. It is a NA study. The enrollment target is 74 participants. The study started on 2020-02-03. Estimated completion is 2023-02-02.

What conditions does trial NCT04186221 study?

This clinical trial studies the following conditions: Liver Transplant.

What interventions are being tested in trial NCT04186221?

The interventions under investigation include: OCS Liver System (DEVICE).

Who is sponsoring clinical trial NCT04186221?

This trial is sponsored by TransMedics, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04186221 being conducted?

This trial has 17 study locations across California, Florida, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Liver Transplant

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04186221's enrollment target sits among peer trials

74 10th of 19 higher than 9 of 19 other Liver Transplant trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Liver Transplant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03422731 · 74 participants · Early Phase 1

    Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

  • NCT03804853 · 74 participants · NA

    Rehabilitation Following Reverse Total Shoulder Arthroplasty

  • NCT04065776 · 74 participants · NA

    Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

  • NCT04771156 · 74 participants · Phase 4

    Ketorolac in Palatoplasty

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04186221, the US trial registry maintained by the National Library of Medicine. NCT04186221 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.